Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

Malignant Glioma Clinical Trial

Official title:

Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02023346
• Other study ID #: 13-253
• Status: Completed
• Start date: December 2013
• Est. completion date: October 30, 2018

Study information

• Verified date: October 2018
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: October 30, 2018
• Est. primary completion date: October 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patient Inclusion Criteria

• Age greater than or equal to 18

• Diagnosis of any WHO grade III or IV glioma

• Admitted to the inpatient Neurology service

• Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in English

Caregiver Inclusion Criteria

• Age greater than or equal to 18

• Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance.

• The patient has himself or herself agreed to participate in this study

Exclusion Criteria:

Patient Exclusion Criteria

• A patient will be excluded if the Glasgow Coma Scale is less than 15. The patient must be oriented to self, age, place, and year, and month.

• Aphasia precluding comprehension and verbalization of consent to participate

• Patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. This evaluation will take place for otherwise eligible and willing participants, and it will be performed by the NP or MD clinician who is obtaining informed consent and will be documented in the medical record.

Caregiver Exclusion Criteria

• No eligible caregivers who can complete the brief assessment in person or via telephone will be excluded

Related Conditions & MeSH terms

• Glioma
• Malignant Glioma

Intervention

Behavioral:
• surveys and cognitive tests

Locations

Country	Name	City	State
United States	Memoral Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	measure prognostic awareness	Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center